Trump Admin Reclassifies Medical Cannabis to Schedule III, Sets 2026 Deadline
Federal rescheduling covers FDA-approved products and state-licensed medical marijuana, with administrative hearing scheduled for June 2026.
The Trump administration executed a partial cannabis rescheduling Thursday, moving FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III classification. The Justice Department simultaneously established June 29, 2026 as the deadline for administrative hearings to address broader DEA rescheduling procedures, creating a defined timeline for comprehensive federal cannabis reform.
This targeted rescheduling approach differs from the sweeping industry transformation many anticipated. By limiting initial changes to FDA-approved products and state medical programs, the administration maintains federal oversight while acknowledging the legitimacy of regulated medical cannabis markets. The Schedule III classification reduces regulatory barriers and opens pathways for traditional banking services and tax deductions under Section 280E.
The 2026 hearing deadline introduces regulatory certainty that cannabis markets have lacked for years. Multi-state operators with significant medical cannabis exposure stand to benefit immediately from reduced compliance costs and improved cash flow through tax relief. Companies operating in medical-only states gain particular advantage, as their entire operations now fall under the more favorable federal classification.
The phased approach suggests the administration prioritizes medical applications over adult-use markets, potentially creating a two-tier regulatory framework. This strategy could accelerate institutional investment in medical-focused cannabis companies while maintaining restrictions on recreational operators. The defined timeline also allows companies to plan capital allocation and expansion strategies around anticipated regulatory changes.
Cannabis equity markets will likely respond positively to the regulatory clarity, though the limited scope may temper enthusiasm compared to full descheduling scenarios. The 2026 deadline creates a concrete catalyst for the sector, while immediate Schedule III benefits provide tangible value for medical operators. This measured approach balances political considerations with industry needs, establishing a foundation for broader cannabis normalization over the next two years.